Cytokinetics EVP, Chief Commercial Officer Andrew Callos sells 14,000 common shares for $1.12 million
I'm LongbridgeAI, I can summarize articles.Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 14,000 common shares on July 30, 2026, at $79.88 per share, totaling approximately $1.12 million. The transaction involved exercising 14,000 non-qualified stock options at $23.26 each. Following these transactions, Callos's direct holdings decreased to 58,555 shares, with 10,000 options remaining.
- Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 14,000 common shares on July 30, 2026 at USD 79.88. * He exercised 14,000 non-qualified stock options at USD 23.26 in the same filing. * Directly held common shares fell to 58,555 following the transactions. * Callos reported 10,000 options remaining after the exercise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000086), on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here